CVS Health Clinical Trial Services to recruit diabetes, chronic kidney disease patients
CVS Health Clinical Trial Services and ProKidney today announced a collaboration to enroll patients with Type 2 diabetes and chronic kidney disease into the proact 1 (REGEN-006) Phase 3 clinical trial of REACT.
ProKidney is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease. ProKidney’s lead product candidate, REACT (REnal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function, the company said.
[Read more: How retail pharmacy is entering clinical trial services]
Clinical Trial Services will recruit patients at 39 proact 1 (REGEN-006) clinical sites, using a machine learning model to identify patient populations that align with trial inclusion/exclusion criteria.
CVS Health said it is committed to kidney health and chronic disease mitigation among its network of patients; this is an opportunity to educate its patients about the opportunity to participate in clinical research.
[Read more: CVS Health debuts clinical trial services business]
ProKidney’s Phase 3 global clinical trials are based on interim analyses from a Phase 2 trial showing the potential for REACT to slow, if not reverse, the typical progressive decline in renal function seen in diabetic CKD patients and which also garnered Regenerative Medicine Advanced Therapeutic designation for REACT.